These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 30235203)
1. Pseudomonas aeruginosa displays a dormancy phenotype during long-term survival in water. Lewenza S; Abboud J; Poon K; Kobryn M; Humplik I; Bell JR; Mardan L; Reckseidler-Zenteno S PLoS One; 2018; 13(9):e0198384. PubMed ID: 30235203 [TBL] [Abstract][Full Text] [Related]
2. A single amino acid substitution in PmrB is associated with polymyxin B resistance in clinical isolate of Pseudomonas aeruginosa. Abraham N; Kwon DH FEMS Microbiol Lett; 2009 Sep; 298(2):249-54. PubMed ID: 19663916 [TBL] [Abstract][Full Text] [Related]
3. Aerosolized Polymyxin B for Treatment of Respiratory Tract Infections: Determination of Pharmacokinetic-Pharmacodynamic Indices for Aerosolized Polymyxin B against Pseudomonas aeruginosa in a Mouse Lung Infection Model. Lin YW; Zhou Q; Onufrak NJ; Wirth V; Chen K; Wang J; Forrest A; Chan HK; Li J Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559256 [TBL] [Abstract][Full Text] [Related]
4. Novel drug targets in cell wall biosynthesis exploited by gene disruption in Pseudomonas aeruginosa. Elamin AA; Steinicke S; Oehlmann W; Braun Y; Wanas H; Shuralev EA; Huck C; Maringer M; Rohde M; Singh M PLoS One; 2017; 12(10):e0186801. PubMed ID: 29045498 [TBL] [Abstract][Full Text] [Related]
5. Comparison of biofilm formation and antibiotic resistance pattern of Pseudomonas aeruginosa in human and environmental isolates. Gholami S; Tabatabaei M; Sohrabi N Microb Pathog; 2017 Aug; 109():94-98. PubMed ID: 28549926 [TBL] [Abstract][Full Text] [Related]
6. Activity of AMP2041 against human and animal multidrug resistant Pseudomonas aeruginosa clinical isolates. Cabassi CS; Sala A; Santospirito D; Alborali GL; Carretto E; Ghibaudo G; Taddei S Ann Clin Microbiol Antimicrob; 2017 Mar; 16(1):17. PubMed ID: 28335779 [TBL] [Abstract][Full Text] [Related]
7. Genotypic and phenotypic analyses of a Pseudomonas aeruginosa chronic bronchiectasis isolate reveal differences from cystic fibrosis and laboratory strains. Varga JJ; Barbier M; Mulet X; Bielecki P; Bartell JA; Owings JP; Martinez-Ramos I; Hittle LE; Davis MR; Damron FH; Liechti GW; Puchałka J; dos Santos VA; Ernst RK; Papin JA; Albertí S; Oliver A; Goldberg JB BMC Genomics; 2015 Oct; 16():883. PubMed ID: 26519161 [TBL] [Abstract][Full Text] [Related]
8. Unveiling the early events of Pseudomonas aeruginosa adaptation in cystic fibrosis airway environment using a long-term in vitro maintenance. Sousa AM; Monteiro R; Pereira MO Int J Med Microbiol; 2018 Dec; 308(8):1053-1064. PubMed ID: 30377031 [TBL] [Abstract][Full Text] [Related]
10. Extracellular DNA controls expression of Lewenza S; Johnson L; Charron-Mazenod L; Hong M; Mulcahy-O'Grady H J Med Microbiol; 2020 Jun; 69(6):895-905. PubMed ID: 32242794 [No Abstract] [Full Text] [Related]
11. Anti-biofilm and resistance suppression activities of CXA-101 against chronic respiratory infection phenotypes of Pseudomonas aeruginosa strain PAO1. Riera E; Macià MD; Mena A; Mulet X; Pérez JL; Ge Y; Oliver A J Antimicrob Chemother; 2010 Jul; 65(7):1399-404. PubMed ID: 20435779 [TBL] [Abstract][Full Text] [Related]
12. Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance. Walsh CC; Landersdorfer CB; McIntosh MP; Peleg AY; Hirsch EB; Kirkpatrick CM; Bergen PJ J Antimicrob Chemother; 2016 Aug; 71(8):2218-29. PubMed ID: 27118778 [TBL] [Abstract][Full Text] [Related]
13. Pleiotropic effects of temperature-regulated 2-OH-lauroytransferase (PA0011) on Pseudomonas aeruginosa antibiotic resistance, virulence and type III secretion system. Wang B; Li B; Liang Y; Li J; Gao L; Chen L; Duan K; Shen L Microb Pathog; 2016 Feb; 91():5-17. PubMed ID: 26596709 [TBL] [Abstract][Full Text] [Related]
14. The exclusion of dead bacterial cells is essential for accurate molecular analysis of clinical samples. Rogers GB; Marsh P; Stressmann AF; Allen CE; Daniels TV; Carroll MP; Bruce KD Clin Microbiol Infect; 2010 Nov; 16(11):1656-8. PubMed ID: 20148918 [TBL] [Abstract][Full Text] [Related]
16. Adaptive resistance to polymyxin in Pseudomonas aeruginosa due to an outer membrane impermeability mechanism. Gilleland HE; Farley LB Can J Microbiol; 1982 Jul; 28(7):830-40. PubMed ID: 6293694 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of heteroresistance to polymyxin B among carbapenem-susceptible and -resistant Pseudomonas aeruginosa. Hermes DM; Pormann Pitt C; Lutz L; Teixeira AB; Ribeiro VB; Netto B; Martins AF; Zavascki AP; Barth AL J Med Microbiol; 2013 Aug; 62(Pt 8):1184-1189. PubMed ID: 23699064 [TBL] [Abstract][Full Text] [Related]
18. Small colony variants of Pseudomonas aeruginosa in chronic bacterial infection of the lung in cystic fibrosis. Evans TJ Future Microbiol; 2015; 10(2):231-9. PubMed ID: 25689535 [TBL] [Abstract][Full Text] [Related]
19. Polymyxin B in Combination with Enrofloxacin Exerts Synergistic Killing against Extensively Drug-Resistant Pseudomonas aeruginosa. Lin YW; Yu HH; Zhao J; Han ML; Zhu Y; Akter J; Wickremasinghe H; Walpola H; Wirth V; Rao GG; Forrest A; Velkov T; Li J Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29632010 [TBL] [Abstract][Full Text] [Related]
20. PhoP-PhoQ homologues in Pseudomonas aeruginosa regulate expression of the outer-membrane protein OprH and polymyxin B resistance. Macfarlane EL; Kwasnicka A; Ochs MM; Hancock RE Mol Microbiol; 1999 Oct; 34(2):305-16. PubMed ID: 10564474 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]